

Sarah a Martin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9608343/publications.pdf>

Version: 2024-02-01

22
papers

1,723
citations

567281

15
h-index

713466

21
g-index

22
all docs

22
docs citations

22
times ranked

3201
citing authors

#	ARTICLE	IF	CITATIONS
1	Carvedilol targets β^2 -arrestins to rewire innate immunity and improve oncolytic adenoviral therapy. <i>Communications Biology</i> , 2022, 5, 106.	4.4	3
2	A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma. <i>Cancers</i> , 2022, 14, 2527.	3.7	8
3	Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma. <i>Investigational New Drugs</i> , 2021, 39, 644-657.	2.6	4
4	Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer. <i>Cell Death and Disease</i> , 2021, 12, 395.	6.3	5
5	The emerging relationship between metabolism and DNA repair. <i>Cell Cycle</i> , 2021, 20, 943-959.	2.6	12
6	Targeted therapy for L1MD1-deficient non-small cell lung cancer subtypes. <i>Cell Death and Disease</i> , 2021, 12, 1075.	6.3	3
7	MLH1 deficiency leads to deregulated mitochondrial metabolism. <i>Cell Death and Disease</i> , 2019, 10, 795.	6.3	29
8	Drug-Repositioning Screens Identify Triamterene as a Selective Drug for the Treatment of DNA Mismatch Repair Deficient Cells. <i>Clinical Cancer Research</i> , 2017, 23, 2880-2890.	7.0	19
9	Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1. <i>Cell Reports</i> , 2016, 16, 1604-1613.	6.4	47
10	RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian Cancer. <i>Molecular Cancer Research</i> , 2016, 14, 44-55.	3.4	15
11	Targeting Mismatch Repair defects: A novel strategy for personalized cancer treatment. <i>DNA Repair</i> , 2016, 38, 135-139.	2.8	23
12	DNA Mismatch Repair and Oxidative DNA Damage: Implications for Cancer Biology and Treatment. <i>Cancers</i> , 2014, 6, 1597-1614.	3.7	100
13	Exploiting DNA mismatch repair deficiency as a therapeutic strategy. <i>Experimental Cell Research</i> , 2014, 329, 110-115.	2.6	55
14	Carbonic Anhydrase 9 Expression Increases with Vascular Endothelial Growth Factor-Targeted Therapy and Is Predictive of Outcome in Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , 2014, 66, 956-963.	1.9	38
15	Oxidative Stress and the DNA Mismatch Repair Pathway. <i>Antioxidants and Redox Signaling</i> , 2013, 18, 2420-2428.	5.4	45
16	Parallel High-Throughput RNA Interference Screens Identify PINK1 as a Potential Therapeutic Target for the Treatment of DNA Mismatch Repair-Deficient Cancers. <i>Cancer Research</i> , 2011, 71, 1836-1848.	0.9	79
17	DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1. <i>Cancer Cell</i> , 2010, 17, 235-248.	16.8	181
18	Therapeutic Targeting of the DNA Mismatch Repair Pathway. <i>Clinical Cancer Research</i> , 2010, 16, 5107-5113.	7.0	123

#	ARTICLE	IF	CITATIONS
19	Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nature Reviews Clinical Oncology, 2010, 7, 197-208.	27.6	189
20	Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene <i>MSH2</i> . EMBO Molecular Medicine, 2009, 1, 323-337.	6.9	154
21	Synthetic lethal targeting of <i>PTEN</i> mutant cells with PARP inhibitors. EMBO Molecular Medicine, 2009, 1, 315-322.	6.9	582
22	Statin Treatment as a Targeted Therapy for APC-Mutated Colorectal Cancer. Frontiers in Oncology, 0, 12, .	2.8	9